OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

April 27, 2023

Biotechnology

BrainStorm Issues 2024 Letter to Shareholders

December 30, 2024
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

December 20, 2024
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

December 20, 2024
INOVIO Announces Pricing of $30 Million Public Offering

December 13, 2024